Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms

Nicholas Hamilton, Ta Chiang Liu, Antonino Cavatiao, Kareem Mawad, Ling Chen, Steven S. Strasberg, David C. Linehan, Dengfeng Cao, William G. Hawkins

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Pancreatic neuroendocrine neoplasms are rare malignancies for which the ideal staging method remains controversial. Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis in neuroendocrine neoplasms. We sought to test the predictive ability of Ki-67 staining for disease recurrence and overall survival (OS) in pancreatic neuroendocrine neoplasms. Methods: The medical records of patients who underwent pancreatic resection for pancreatic neuroendocrine neoplasms at a tertiary referral hospital from 1994 to 2009 were reviewed. The pathologic specimens of all were stained for Ki-67 and recorded as percentage of cells staining positive per high-powered field. The 10-year disease-free and OSs were analyzed. Results: We identified 140 patients. Gender and age were not associated with increased risk of disease recurrence. Patients with tumors >4 cm or with Ki-67 staining >9% were more likely to have disease recurrence (P = .0454 and .047) and have decreased OS (P <.0001 and .0007). Conclusion: Increasing tumor size and increasing Ki-67 staining both correlate with increased risk of disease recurrence and decreased OS. Designing a staging system that incorporates both of these clinical variables will enable better identification of patients at risk for recurrent pancreatic neuroendocrine neoplasms.

Original languageEnglish (US)
Pages (from-to)107-113
Number of pages7
JournalSurgery (United States)
Volume152
Issue number1
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Recurrence
Staining and Labeling
Survival
Neoplasms
Tertiary Care Centers
Medical Records
Cell Proliferation

ASJC Scopus subject areas

  • Surgery

Cite this

Hamilton, N., Liu, T. C., Cavatiao, A., Mawad, K., Chen, L., Strasberg, S. S., ... Hawkins, W. G. (2012). Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery (United States), 152(1), 107-113. https://doi.org/10.1016/j.surg.2012.02.011

Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. / Hamilton, Nicholas; Liu, Ta Chiang; Cavatiao, Antonino; Mawad, Kareem; Chen, Ling; Strasberg, Steven S.; Linehan, David C.; Cao, Dengfeng; Hawkins, William G.

In: Surgery (United States), Vol. 152, No. 1, 07.2012, p. 107-113.

Research output: Contribution to journalArticle

Hamilton, N, Liu, TC, Cavatiao, A, Mawad, K, Chen, L, Strasberg, SS, Linehan, DC, Cao, D & Hawkins, WG 2012, 'Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms', Surgery (United States), vol. 152, no. 1, pp. 107-113. https://doi.org/10.1016/j.surg.2012.02.011
Hamilton, Nicholas ; Liu, Ta Chiang ; Cavatiao, Antonino ; Mawad, Kareem ; Chen, Ling ; Strasberg, Steven S. ; Linehan, David C. ; Cao, Dengfeng ; Hawkins, William G. / Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. In: Surgery (United States). 2012 ; Vol. 152, No. 1. pp. 107-113.
@article{c4449990daf742ebbc557c296c5d5ee4,
title = "Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms",
abstract = "Background: Pancreatic neuroendocrine neoplasms are rare malignancies for which the ideal staging method remains controversial. Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis in neuroendocrine neoplasms. We sought to test the predictive ability of Ki-67 staining for disease recurrence and overall survival (OS) in pancreatic neuroendocrine neoplasms. Methods: The medical records of patients who underwent pancreatic resection for pancreatic neuroendocrine neoplasms at a tertiary referral hospital from 1994 to 2009 were reviewed. The pathologic specimens of all were stained for Ki-67 and recorded as percentage of cells staining positive per high-powered field. The 10-year disease-free and OSs were analyzed. Results: We identified 140 patients. Gender and age were not associated with increased risk of disease recurrence. Patients with tumors >4 cm or with Ki-67 staining >9{\%} were more likely to have disease recurrence (P = .0454 and .047) and have decreased OS (P <.0001 and .0007). Conclusion: Increasing tumor size and increasing Ki-67 staining both correlate with increased risk of disease recurrence and decreased OS. Designing a staging system that incorporates both of these clinical variables will enable better identification of patients at risk for recurrent pancreatic neuroendocrine neoplasms.",
author = "Nicholas Hamilton and Liu, {Ta Chiang} and Antonino Cavatiao and Kareem Mawad and Ling Chen and Strasberg, {Steven S.} and Linehan, {David C.} and Dengfeng Cao and Hawkins, {William G.}",
year = "2012",
month = "7",
doi = "10.1016/j.surg.2012.02.011",
language = "English (US)",
volume = "152",
pages = "107--113",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms

AU - Hamilton, Nicholas

AU - Liu, Ta Chiang

AU - Cavatiao, Antonino

AU - Mawad, Kareem

AU - Chen, Ling

AU - Strasberg, Steven S.

AU - Linehan, David C.

AU - Cao, Dengfeng

AU - Hawkins, William G.

PY - 2012/7

Y1 - 2012/7

N2 - Background: Pancreatic neuroendocrine neoplasms are rare malignancies for which the ideal staging method remains controversial. Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis in neuroendocrine neoplasms. We sought to test the predictive ability of Ki-67 staining for disease recurrence and overall survival (OS) in pancreatic neuroendocrine neoplasms. Methods: The medical records of patients who underwent pancreatic resection for pancreatic neuroendocrine neoplasms at a tertiary referral hospital from 1994 to 2009 were reviewed. The pathologic specimens of all were stained for Ki-67 and recorded as percentage of cells staining positive per high-powered field. The 10-year disease-free and OSs were analyzed. Results: We identified 140 patients. Gender and age were not associated with increased risk of disease recurrence. Patients with tumors >4 cm or with Ki-67 staining >9% were more likely to have disease recurrence (P = .0454 and .047) and have decreased OS (P <.0001 and .0007). Conclusion: Increasing tumor size and increasing Ki-67 staining both correlate with increased risk of disease recurrence and decreased OS. Designing a staging system that incorporates both of these clinical variables will enable better identification of patients at risk for recurrent pancreatic neuroendocrine neoplasms.

AB - Background: Pancreatic neuroendocrine neoplasms are rare malignancies for which the ideal staging method remains controversial. Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis in neuroendocrine neoplasms. We sought to test the predictive ability of Ki-67 staining for disease recurrence and overall survival (OS) in pancreatic neuroendocrine neoplasms. Methods: The medical records of patients who underwent pancreatic resection for pancreatic neuroendocrine neoplasms at a tertiary referral hospital from 1994 to 2009 were reviewed. The pathologic specimens of all were stained for Ki-67 and recorded as percentage of cells staining positive per high-powered field. The 10-year disease-free and OSs were analyzed. Results: We identified 140 patients. Gender and age were not associated with increased risk of disease recurrence. Patients with tumors >4 cm or with Ki-67 staining >9% were more likely to have disease recurrence (P = .0454 and .047) and have decreased OS (P <.0001 and .0007). Conclusion: Increasing tumor size and increasing Ki-67 staining both correlate with increased risk of disease recurrence and decreased OS. Designing a staging system that incorporates both of these clinical variables will enable better identification of patients at risk for recurrent pancreatic neuroendocrine neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=84862881173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862881173&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2012.02.011

DO - 10.1016/j.surg.2012.02.011

M3 - Article

VL - 152

SP - 107

EP - 113

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 1

ER -